SGLT2 inhibitors can significantly reduce the risk of hospitalization for heart failure (HF) and death from cardiovascular causes in patients with diabetes and HF. However, the diagnosis of HF is difficult. Scientists from St. Gallen therefore wanted to determine the prevalence of heart failure in patients with diabetes with and without SGLT2i in order to establish whether treatment guidelines need to be tightened and regular screening for HF introduced.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- PancNEN, PancNET & PancNEC
Neuroendocrine tumors of the pancreas
- Heart failure
Interventional treatment of the tricuspid valve
- Lipoprotein(a)
Current and future treatment options
- Lichen sclerosus
Topical corticosteroids still the first choice
- Breast Cancer
On the trail of triple-negative breast cancer
- Headache treatment
The therapy of migraine
- Sleep disorders in old age
Recognize insomnia, treat it and avoid cognition disorders
- From symptom to diagnosis